中文 日本語

Insights & News

IP Updates AFD News IP Alerts

2021-09-19

AFD China Recognized as a Recommended Firm in Patent Prosecution and Patent Contentious by Asia IP

Recently, renowned intellectual property magazine Asia IP announced the result of its 2021 Patent Survey, which has been published in the September issue of Asia IP. In this survey, AFD China was recognized as a recommended firm for its outstanding perfor

2021-08-19

AFD China was once again recommended by IAM Patent 1000

Recently, world-renowned IP business media platform Intellectual Asset Management (IAM) released the 2021 edition of IAM Patent 1000. AFD China was again recognized as a leading firm in the listing. Since 2016, this has been the fifth time AFD China was r

2021-07-02

The 22nd China Patent Award Was Released – AFD China's Clients Won One Gold Award and One Excellence Award

On June 24, 2021, the winners of the 22nd China Patent Award were announced by the China Intellectual Property Administration (CNIPA). The China Patent Award is co-organized by the China Intellectual Property Administration and the World Intellectual Prop

2021-07-02

AFD China Recognized as a Recommended Firm in Trademark Prosecution by Asia IP

Recently, renowned intellectual property magazine Asia IP announced the result of its 2021 Trademark Survey, which has been published in the May issue of Asia IP. In this survey, AFD China was ranked as a Tier 2 firm for its outstanding performance in tra

2021-06-18

AFD China Was Once Again Honored as An AAAAA-Level (Top Tier) Patent Agency

On May 12, 2021, Beijing Patent Attorneys Association announced the rating results of the year 2020 for patent agencies in Beijing. AFD China was once again rated as an AAAAA-level patent agency. AFD China has been rated as an AAAAA-level patent agency si

2021-05-21

AFD China Won China IP Awards 2021

Recently, reputable intellectual property magazine Asia IP launched its 2021 China IP Awards, announcing the winners among top IP firms in each practice area. AFD China, by virtue of its outstanding expertise in pharma and biotech IP matters as well as it
  • <
  • <<
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • >>
  • >